AHRQ No Evidence to Support Off-Label Uses of Atypical Antipsychotics
"Most off-label use occurs without scientific support."
"Most off-label use occurs without scientific support."
NY Times reports: In March 2002, Lilly rejected plans to give psychiatrists guidance about how
to treat diabetes, "worrying that doing so would tarnish Zyprexa's reputation."
U.S. State Attorneys General should investigate the fraudulent marketing of the atypical neuroleptic drugs-and FDA's role in helping conceal the truth.
The lead story in The New York Times on Thanksgiving day (below) acknowledged several facts demonstrating that children are the victims of major medical malpractice:
Dr. E. Jane Costello, a professor of psychiatry and behavioral sciences at Duke University, acknowledges: “The system of diagnosis is still 200 to 300 years behind other branches of medicine.” Psychiatry also fails to be guided by an evidence-based positive benefit / risk assessment of its prescribed treatments.
The ethics of this radical drug experiment is being challenged by Dr. Jerald Block, a forthright psychiatrist and experienced system's analyst. His critical appraisal, published in the Bioethics Forum, Hastings Center Report.
The New York Times reports: "For big drug companies, the new Medicare prescription benefit is proving to be a financial windfall larger than even the most optimistic Wall Street analysts had predicted."
An Orwellian nightmare is being implemented on infants even as the evidence demonstrates that the psychiatry's practice guidelines are corrupted by
industry.
Medical researchers who commit fraud and research misconduct are caught only when a person of conscience steps up to the plate and blows the whistle. There are no systemic, independent checks and balances to prevent research fraud or abuse of patients.
Federal Study Finds No Benefit of New Antipsychotic Drugs – WashPost/Wall StreetJ/NY Times Tue, 20 Sep 2005 The findings of a $44 million government sponsored study, CATIE, published in The New England Journal of Medicine, comparing an older generic antipsychotic to four new atypical antipsychotics, undercut the legitimacy of psychiatry’s…
Lilly to Add Suicide Warning to Strattera – Medicaid May shrink $5.5 Billion spending on Schizophrenia Drug Thu, 29 Sep 2005 Reuters reports that Eli Lilly is adding a Black Box suicide warning to the Strattera label. Strattera has been promoted as a “non stimulant” treatment for ADHD. Since ADHD…
Failed Drug Treatments for Schizophrenia–Letters to the Editor – NYT Fri, 23 Sep 2005 Letters to the NY Times editor (below) demonstrate the combative reaction of stakeholders in the psychotropic drug industry to the evidence-based overthrow of psychiatry’s treatment recommendations. Psychiatrists who have financial contracts with psychotropic drug manfuacturers, have…